[PE27] Poster Session 27
Other skin diseases 2

[PE27-9] Long-term efficacy and safety of lanadelumab in patients with hereditary angioedema: interim results from the HELP open-label extension study

Neil Inhaber¹, Marc A Riedl², Paula J Busse³, Raffi Tachdjian⁴, Daniel Soteres⁵, James Hao⁶, Peng Lu⁶, Aleena Banerji⁷ (1.Takeda Pharmaceutical Company Limited, USA, 2.Division of Rheumatology, Allergy & Immunology, University of California San Diego, USA, 3.Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, USA, 4.AIRE Medical of Los Angeles, University of California Los Angeles, USA, 5.Asthma and Allergy Associates PC, USA, 6.Shire, a Takeda company, USA, 7.Massachusetts General Hospital, Harvard Medical School, USA)